The intermediate-term incidence of strut malapposition (SM) and uncovered struts (US), and the degree of neointimal thickness (NIT) according to stent type have not been characterized.
Introduction
Stent thrombosis (ST) is one of the most severe complications after percutaneous coronary intervention (PCI), and its occurrence has been associated with delayed and deficient endothelial coverage of stent struts, vascular inflammation and hypersensitivity reactions, strut fracture, and possibly malapposition. 1 -3 In addition, the development of neoatherosclerosis within neointimal hyperplasia with subsequent plaque rupture and thrombosis may represent a frequent cause of ST and coronary occlusion. 4, 5 Second-generation drug-eluting stents (DES) have reduced the incidence of ST compared with first-generation DES and bare metal stents (BMS). 5 The exact mechanisms underlying this finding remain speculative, although technological improvements including enhanced polymer biocompatibility, bioresorbable polymers, thinner strut platforms with more rapid and complete endothelialization, and a reduced propensity to strut fracture may have reduced the thrombogenicity of contemporary DES. 6, 7 The high resolution of optical coherence tomography (OCT) 7, 8 enables characterization of stent healing and vascular responses, as well as accurate quantification of neointimal hyperplasia after stent implantation. Recent OCT studies have reported an association between uncovered stent struts and late ST following DES implantation, 9 although the incidence and impact of strut malapposition (SM), uncovered struts (US), and neointimal thickness (NIT) on ST remain uncertain. These findings and their implications may also vary with different stent types. We therefore performed a systematic review and meta-analysis to evaluate the frequency and clinical correlations of SM, US, and the degree of NIT by OCT according to stent type.
Methods
The present study utilized the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, the amendment to the Quality of Reporting of Meta-analyses (QUOROM) 10 statement, and recommendations from the Cochrane Collaboration and Meta-analysis of Observational Studies in Epidemiology (MOOSE).
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Search strategy
Two cardiologists (M.I. and F.D.A.) searched MEDLINE/PubMed, CEN-TRAL, and international congress reports for pertinent articles published in English with the following terms, incorporating wild cards (*): 'coronary*', 'stent*', 'OCT', 'stent malapposition', and 'uncovered struts'.
Study selection
Two co-authors (M.I. and F.D.A.) reviewed the retrieved titles and abstracts, with divergences resolved after consensus. Reports with the following selection criteria were retained (all had to be present): (i) human studies, (ii) ≥50 patients undergoing PCI with stent implantation, and (iii) OCT performed between 6 and 12 months from the time of stent implantation. Exclusion criteria included: (i) duplicate reporting (in which case the manuscript reporting the largest number of overall patients was retained), (ii) only grouped results reported for different types of stents, and (iii) cut-off distance for SM which differed by .10% from the mean of pooled data.
Data extraction
From the eligible studies, the two reviewers (M.I. and F.D.A.) abstracted the following data on pre-specified electronic forms with any discrepancies resolved by consensus: authors, journal, and year of publication, location of the study group, baseline, angiographic and procedural features, SM, US, NIT, and subclinical thrombi. Stent coverage was classified as not visible/incomplete when there were one or more stent struts with no visible tissue coverage, or as complete when tissue was seen overlying the strut. The thickness of the tissue coverage on the luminal side of each strut was measured at the middle of the long axis of the strut. A linear measurement line was drawn from the endoluminal leading edge perpendicular to the long axis of the strut towards the luminal leading edge of the strut. Struts were classified as apposed when the strut was in contact with the vessel wall or malapposed if protruding into the lumen at a distance greater than the strut thickness (according to each different stent type). Discrepancies regarding software offline image analysis, quantification of SM, and cut-off distance to define the SM were reported in results.
The incidences of SM and of US were the co-primary end points of the present study (reported respectively as the ratio of the number of total malapposed struts to the number of total analysed struts, and the number of total US to the number of total analysed struts), while NIT was the secondary end point of the study. The impact of clinical and angiographic characteristics on the primary end points was tested by meta-regression analysis.
Internal validity and quality appraisal
Two reviewers (M.I. and F.D.A.) evaluated the quality of the studies on pre-specified electronic forms, with divergences resolved by consensus. According to the MOOSE, the Jadad scale and the Newcastle -Ottawa scale (NOS), we separately abstracted and appraised study design, setting, data source, as well as (in keeping with the Cochrane Collaboration approach) the risk of analytical, selection, adjudication, detection, and attrition bias (expressed as low, moderate, or high risk of bias, or incomplete reporting leading to inability to ascertain the underlying risk of bias).
Data analysis and synthesis
Continuous variables are reported as median (1st and 3rd quartile). Categorical variables are expressed as n/N (%). Statistical pooling for incidence estimates of SM and US was performed according to a random-effect model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals, using RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre and Copenhagen, Denmark). Study bias was appraised by graphical inspection of funnel plots. Hypothesis testing for superiority was set at the two-tailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the two-tailed 0.10 level and was based on the Cochran Q test, with I 2 values of 25, 50, and 75% representing mild, moderate, and severe heterogeneity, respectively. Meta-regression analysis was performed with comprehensive meta-analysis, reporting results as Beta [i.e. the increase or decrease in the rates of ST, all-cause death, myocardial infarction (MI), and target lesion revascularization (TLR)].
Results
A total of 454 studies were initially appraised at the abstract level and 13 full-text studies were retained. Of these, one study was excluded because of duplicate reporting, 15 leaving 12 studies that met the criteria for inclusion in the present meta-analysis ( Figure 1 and Table 1 ).
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Among the included studies, OCT assessment was performed on 280 652 struts in 921 patients. Pooled baseline patient characteristics are reported in Table 2 , while the baseline characteristics from each included study appear in Supplementary data online, Table SA. The median age was 63.2 (60.0, 68.1) years, 29.8% of patients were female, and 28.0% had diabetes mellitus. The left anterior descending artery was the most frequently evaluated vessel (48.3%), and the mean stent length was 29.9 (23.4, 34.0) mm. The main indication for the 6-12-month angiographic and OCT assessment procedure was for routine follow-up (87.2%).
At mid-term (6 -12 months after stent implantation), the incidences of SM and US were 5.0 and 7.8% respectively, and the mean NIT was 206 mm. Among first-generation DES, sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) had similar rates of SM (2.1 vs. 2.2%, respectively, Figure 2 ), but SES had more frequent US (8.8 vs. 3.1%, Figure 3 ). Among secondgeneration DES, biolimus-eluting stents (BES) had the greatest rates of SM and US (2.7 and 7.7%, respectively), compared with everolimus-eluting stents (EES; 0.9 and 2.8% respectively) and fast-release zotarolimus-eluting stents (ZES) (0.1 and 0.4%, respectively). Bioresorbable vascular scaffolds (BVS) tended to have a higher rate of SM (3.8%) compared with second-generation DES, but a low rate of US (1.6%). SES, EES, and BMS had the lowest extent of NIT. Finally, BMS had a low prevalence of both SM and US (0.1 and 0.3%, respectively), but the greatest NIT (340 + 343 mm) (Figure 4) . Only 5 studies 17, 18, 21, 22, 28 reported the presence of subclinical thrombi, with SES having the highest prevalence (29%) ( Figure 5 ).
Sensitivity analysis for clinical and angiographic characteristics
As shown in Supplementary data online, Tables SB and SC, none of the clinical and angiographic characteristics tested at metaregression analysis appeared to influence the rate of SM or US. Conversely, hyperlipidaemia and presentation with an acute coronary syndrome correlated with NIT ( Figure 6 , Supplementary data online, Table SD ). Of note, Asian patients had higher rates of US and thinner NIT compared with Western patients (2.1 vs. 6.0%, and 150.1 + 13.7 vs. 127.9 + 11.1 mm, respectively) ( Figure 7 ).
Publication bias analysis
There was general concordance between studies for the SM cut-off and US criteria (Supplementary data online, Figures SA -SC) . Significant heterogeneity between studies was present for evaluation of Figure SD ).
Discussion
The main findings of the present systemic review and meta-analysis are that by OCT assessment 6-12 months after stent implantation: (i) the rates of strut apposition and coverage, and the extent of neointimal thickening vary across different device types; (ii) secondgeneration DES had improved immediate-term rates of strut apposition and better strut coverage compared with first-generation DES; (iii) BES and SES had the highest US rates, whereas ZES and BMS had the lowest US rates; and (iv) BMS had the greatest NIT. In the past several years, a number of OCT studies have investigated vascular responses to stent implantation in various clinical Optical coherence tomography of stent healing situations. 28 The higher resolution of OCT compared with intravascular ultrasound (IVUS) affords accurate assessment of the degree of SM, US, and NIT at different time periods. 29, 30 The present report is to our knowledge the first systematic review and meta-analysis comparing the intermediate (6 -12-month) healing responses of different stent platforms. We chose to exclude studies with ,50 patients to avoid outlier results from small studies. Moreover, the cut-off distances from the struts to the vessel wall to define stent malapposition have varied between studies and stent types. To avoid this bias, we only included studies in which the cut-off distances differed by ,10% from the pooled mean.
In the present analysis, second-generation DES (especially EES and fast-release ZES) had a lower 6-12-month rate of SM and improved strut coverage compared with first-generation DES. This difference may be due to the thinner struts, improved conformability, and improved biocompatibility of these devices. 31 First-generation DES have also been associated with chronic inflammation and delayed arterial healing (possibly due to pro-inflammatory polymers 32 ), which might contribute to the higher rates of very late ST observed with first-generation DES compared with BMS. 33 Firstand second-generation DES all had reduced NIT compared with BMS, although there were differences between DES, with SES, EES, and BES having the lowest extent of NIT. Second-generation DES have reduced in-stent restenosis to 5 -10%, depending on the lesion subset and DES type. 34 BVS tended to be intermediate in most measures in this study, consistent with their design and prior clinical observations. 34 However, conclusions regarding BVS from this study must be tempered given the differences in patient selection and lesion characteristics between BVS and the other stent types in clinical studies and practice. Overall, EES demonstrated the best combination of low rates of SM and US, with low mean NIT, consistent with the demonstrated safety and efficacy with this device. BES measured somewhat worse than EES for SM and US, although had similar NIT. These findings are consistent with a recent network meta-analysis by Palmerini et al., which reported similar 1-year rates of target vessel revascularization with BES and EES, but higher rates of ST with BES. 35 The explanations underlying this finding may relate to the inflammation that accompanies polymer biodegradation, as well as inherent thromboresistant properties of the EES fluoropolymer.
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Of note, the correlation between the presence of SM and US by OCT and subsequent ST is controversial, and our data should not be used to support a causal relationship. Several studies have failed to demonstrate a relationship between SM and ST. 37 -39 Guagliumi et al. reported that the presence and magnitude of incomplete stent Figure 5 Mid-term evaluation of subclinical thrombi according to different stent type. ZES, zotarolimus-eluted stent; SES, sirolimus-eluted stent; PES, paclitaxel-eluted stent; EES, everolimus-eluted stent. Figure 6 Acute coronary syndrome impact on mid-term NIT at meta-regression analysis. ACS, acute coronary syndrome.
apposition were significantly more common and more pronounced in patients with DES thrombosis compared with those without thrombosis. 9 In this regard, acute SM should be differentiated from late-acquired SM. It is possible that vascular toxicity resulting in positive remodelling and secondary late-acquired malapposition may be related to ST, rather than the geometric disturbances of late malapposition itself. In a multicentre registry, SM was more common with first-generation DES than BMS and was associated with very late definite ST. 40 However, in an IVUS study of 1580 patients receiving PES and BMS, Mintz et al. did not find a relationship between either acute or late-acquired SM and adverse clinical events during long-term follow-up. 38 Similar results were reported in a pooled analysis from the RAVEL, E-SIRIUS, and SIRIUS trials comparing SES and BMS at 4-year follow-up. 41 The discrepancy between studies may be explained by use of OCT vs. IVUS in different studies and by differences in lesion complexity. Finally, it is possible that only large degrees of SM correlate with ST, an infrequent occurrence and thus difficult to study. Of note, several new parameters have been recently proposed such as maximal intima distance, maximal length of consecutive malapposed struts, maximal area, and maximal volume that may provide more clinically relevant information. 42 Data regarding the relevance of these novel parameters are not yet available, warranting further studies. The present study has several limitations. First, it is not a patientlevel analysis, and all the data were derived from observational studies rather than randomized controlled trials. Given the likelihood of confounding, the results of the present study should be viewed as hypothesis generating only and not as solid evidence of causal associations. 43 Particular caution is warranted when assessing the results of meta-regression. Second, differences between studies were present as regards the methodology for evaluation of SM and US, and different analysis systems were used. Some of the observational studies included do suffer from a poor methodological quality, and the higher is the risk of bias of a study the more likely a meta-analytical conclusion could be biased or erroneous. 44 Third, follow-up time was somewhat variable between studies, and correlation with clinical events was inconsistently present and due to the absence of data was not possible to assess therapy impact on the end points. Fourth, substantial OCT data regarding several stent types in current use such as slow-release ZES and EES using a platinum -chromium platform with a bioresorbable polymer, as well as BVS other than Absorb, were not available. Finally, as the present analysis was not a patient-level study and sufficient data were not available for a valid network, statistical comparison between different stent types in the rates of SM, US, and the degree of NIT was not possible. Thus, the relative quantitative measures described in this report should be considered conclusive for inferential testing but may be useful to inform future studies. These limitations notwithstanding, the findings from this summary-level analysis derived from the published OCT studies to date regarding strut apposition and coverage and neointimal thickening between different stent types are provocative. Specifically, second-generation DES demonstrates higher rates of 6 -12 months strut apposition and strut coverage compared with firstgeneration DES. There are differences between devices, however, with EES appearing to have the best combination of mid-term healing and low NIT. The results with BVS are intermediate between contemporary DES and BMS. Further studies are required to determine the extent to which these findings correlate with meaningful clinical differences between devices.
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